Cytokine expression in tears of patients with glaucoma or dry eye disease: A prospective,observational cohort study

Abstract

Background:

The aim of this study was to assess the expression of cytokines/chemokines in tears from patients with non-advanced primary open-angle glaucoma and patients with non-severe dry eye disease versus healthy controls.

Methods:

This prospective, observational cohort study enrolled patients with confirmed or suspected non-advanced primary open-angle glaucoma who received any prostaglandin analogue monotherapy for longer than 6 months, patients with non-severe dry eye disease, and healthy controls. Expression of interleukin-1β, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10, and interleukin-12; tumor necrosis factor α; vascular endothelial growth factor; granulocyte-macrophage colony-stimulating factor; and interferon γ was assessed.

Results:

107 participants were enrolled (primary open-angle glaucoma, n = 41; dry eye disease, n = 30; and healthy controls, n = 36). Compared with healthy controls, interleukin-6 was significantly higher (p = 0.0001) in patients with primary open-angle glaucoma and interleukin-1β (p = 0.0144), interleukin-6 (p < 0.0001), and interleukin-10 (p = 0.0392) were higher in patients with dry eye disease. Compared with patients with dry eye disease, patients with primary open-angle glaucoma had significantly lower levels of interleukin-4 (21.79 vs 20.18 pg/mL; p = 0.0012) and significantly higher levels of vascular endothelial growth factor (367.75 vs 609.28 pg/mL; p = 0.0058), tumor necrosis factor α (14.27 vs 17.93 pg/mL; p = 0.0048), and interleukin-6 (17.95 vs 27.48 pg/mL; p = 0.0145). In patients with primary open-angle glaucoma, interleukin-1β expression (p = 0.0011) was lower than in those who received intraocular pressure–lowering eye drops without preservatives compared with those who received eye drops with preservatives.

Conclusion:

Different cytokine/chemokine expression profiles in tears of patients with primary open-angle glaucoma and dry eye disease strongly suggest the involvement of a variety of signaling pathways in the pathogenesis of these ophthalmic processes.

Keywords

Cytokines dry eye syndrome inflammation primary open-angle glaucoma

Get full access to this article

View all access options for this article.

References

Kwon

Fingert

Kuehn

et al . Primary open-angle glaucoma. N Engl J Med 2009; 360(11): 1113–1124.

Friedman

Wolfs

O’Colmain

et al . Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004; 122(4): 532–538.

Muñoz

West

Rubin

et al . Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study. Arch Ophthalmol 2000; 118(6): 819–825.

Pascolini

Mariotti

SP.

Global estimates of visual impairment: 2010. Br J Ophthalmol 2012; 96(5): 614–618.

Perry

HD.

Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care 2008; 14(Suppl. 3): S79–S87.

Labbé

Brignole-Baudouin

Baudouin

Ocular surface investigations in dry eye. J Fr Ophtalmol 2007; 30(1): 76–97.

Tavares

Fernandes

Bernardes

et al . Dry eye disease. Semin Ophthalmol 2010; 25(3): 84–93.

Tsai

Derby

Holland

et al . Incidence and prevalence of glaucoma in severe ocular surface disease. Cornea 2006; 25(5): 530–532.

Benitez-del-Castillo

Cantu-Dibildox

Galbis-Estrada

et al . Ocular surface morbidities in glaucoma. Eur Ophthal Rev 2013; 7(1): 31–35.

10.

Leung

Medeiros

Weinreb

RN.

Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008; 17(5): 350–355.

11.

Lemij

Hoevenaars

van der Windt

et al . Patient satisfaction with glaucoma therapy: reality or myth? Clin Ophthalmol 2015; 9: 785–793.

12.

Baudouin

Pisella

Fillacier

et al . Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999; 106(3): 556–563.

13.

Medzhitov

Janeway

Jr.

Innate immunity. N Engl J Med 2000; 343(5): 338–344.

14.

Krabbe

Pedersen

Bruunsgaard

Inflammatory mediators in the elderly. Exp Gerontol 2004; 39(5): 687–699.

15.

Stevenson

Chauhan

Dana

Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 2012; 130(1): 90–100.

16.

Suzuki

Tsujikawa

Itabe

et al . Chronic photo-oxidative stress and subsequent MCP-1 activation as causative factors for age-related macular degeneration. J Cell Sci 2012; 125(Pt 10): 2407–2415.

17.

Zoukhri

Effect of inflammation on lacrimal gland function. Exp Eye Res 2006; 82(5): 885–898.

18.

Gallego-Pinazo

Marsiglia

Mrejen

et al . Outer retinal tubulations in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2013; 251(6): 1655–1656.

19.

Yoshida

Ikeda

Notomi

et al . Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 2013; 120(1): e5–e12.

20.

Hodapp

Parrish

RKI

Anderson

Clinical decisions in glaucoma. St. Louis, MI: The C. V. Mosby Co, 1993, pp.52–61.

21.

Schiffman

Christianson

Jacobsen

et al . Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000; 118(5): 615–621.

22.

Galbis-Estrada

Pinazo-Durán

Cantú-Dibildox

et al . Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids. Clin Interv Aging 2013; 8: 711–719.

23.

Pinazo-Durán

Galbis-Estrada

Pons-Vázquez

et al . Effects of a nutraceutical formulation based on the combination of antioxidants and omega-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders. Clin Interv Aging 2013; 8: 139–148.

24.

Enríquez-de-Salamanca

Castellanos

Stern

et al . Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis 2010; 16: 862–873.

25.

Higuchi

Kawakita

Tsubota

IL-6 induction in desiccated corneal epithelium in vitro and in vivo. Mol Vis 2011; 17: 2400–2406.

26.

Tuominen

Tervo

Teppo

et al . Human tear fluid PDGF-BB, TNF-alpha and TGF-beta1 vs corneal haze and regeneration of corneal epithelium and subbasal nerve plexus after PRK. Exp Eye Res 2001; 72(6): 631–641.

27.

Opal

DePalo

VA.

Anti-inflammatory cytokines. Chest 2000; 117(4): 1162–1172.

28.

Pinazo-Durán

Zanón-Moreno

García-Medina

et al . Eclectic ocular comorbidities and systemic diseases with eye involvement: a review. Biomed Res Int 2016; 2016: 6215745.

29.

Baudouin

Hamard

Liang

et al . Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004; 111(12): 2186–2192.

30.

Chong

Jiang

Boey

et al . Tear cytokine profile in medicated glaucoma patients: effect of monocyte chemoattractant protein 1 on early posttrabeculectomy outcome. Ophthalmology 2010; 17(12): 2353–2358.

31.

Boehm

Riechardt

Wiegand

et al . Proinflammatory cytokine profiling of tears from dry eye patients by means of antibody microarrays. Invest Ophthalmol Vis Sci 2011; 52(10): 7725–7730.

32.

Brignole

Pisella

Goldschild

et al . Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci 2000; 41(6): 1356–1363.

33.

Brignole-Baudouin

Baudouin

Aragona

et al . A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. Acta Ophthalmol 2011; 89(7): e591–e157.

34.

Luo

Doshi

et al . Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci 2004; Dec45(12): 4293–4301.

35.

Mok

Kim

et al . Correlations between tear cytokines, chemokines, and soluble receptors and clinical severity of dry eye disease. Invest Ophthalmol Vis Sci 2012; 53(9): 5443–5450.

36.

Wang

Mao

Xie

et al . Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci 2007; 27(2): 304–307.

37.

Benítez del Castillo

Wasfy

Fernandez

et al . An in vivo confocal masked study on corneal epithelium and subbasal nerves in patients with dry eye. Invest Ophthalmol Vis Sci 2004; 45(9): 3030–3035.

38.

Wong

Zhou

et al . Proteomic profiling of inflammatory signaling molecules in the tears of patients on chronic glaucoma medication. Invest Ophthalmol Vis Sci 2011; 52(10): 7385–7391.

39.

Sung

Cui

et al . Effect of topical 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside in a mouse model of experimental dry eye. Invest Ophthalmol Vis Sci 2015; 56(5): 3149–3158.

40.

De Saint Jean

Brignole

Bringuier

et al . Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999; 40(3): 619–630.

41.

Jaenen

Baudouin

Pouliquen

et al . Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17(3): 341–349.

42.

Pisella

Pouliquen

Baudouin

Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86(4): 418–423.

43.

Massingale

Vallabhajosyula

et al . Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009; 28: 1023–1027.

44.

Martinez-de-la-Casa

Perez-Bartolome

Urcelay

et al . Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost. Ocul Surf 2017; 15(4): 723–729.

45.

Jee

Park

Lee

et al . Comparison of treatment with preservative-free versus preserved sodium hyaluronate 0.1% and fluorometholone 0.1% eyedrops after cataract surgery in patients with preexisting dry-eye syndrome. J Cataract Refract Surg 2015; 41(4): 756–763.

46.

Dionne

Redfern

Nichols

et al . Analysis of tear inflammatory mediators: a comparison between the microarray and Luminex methods. Mol Vis 2016; 22: 177–188.